Delving into the Latest Updates on Talquetamab with Synapse

Overview

Basic Info

Drug Type

Bispecific T-cell Engager (BiTE)

Synonyms

DuoBody, TALQUETAMAB-TGVS, JNJ 64407564

+ [5]

Target

CD3 x GPRC5D

Mechanism

CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [2]

Active Indication

Multiple MyelomaPeripheral Stem Cell TransplantationRefractory Multiple Myeloma+ [2]

Inactive Indication-

Originator Organization

Janssen Pharmaceuticals, Inc.

Active Organization

Johnson & Johnson (China) Investment Ltd.Janssen Research & Development LLC

Janssen Pharmaceutica NV

+ [6]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (09 Aug 2023),

Multiple Myeloma

RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Priority Review (CN), Breakthrough Therapy (CN), Orphan Drug (KR), Conditional marketing approval (EU)

Login to view timeline

Structure/Sequence

Sequence Code 10086313H

Source: *****

Sequence Code 10086327L

Source: *****

Sequence Code 453116282H

Source: *****

Sequence Code 525754800L

Source: *****

Induction therapy approaches in recent years have evolved, now utilizing triple or quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients achieve longer remissions with their first- and second-line therapies but also become refractory to most or all three major drug classes earlier. For patients who are refractory to at least 3 of the commonly administered PIs and IMiDs, occurring after 2 lines of therapy in many, the median overall survival is only 5 months. Elderly, frail patients are not often candidates at this point for aggressive therapies like stem cell transplantation and CAR T-cell therapy thus necessitating effective yet tolerable treatments for elderly patients in early relapse (1-3 prior therapy). Talquetamab is a GPRC5DxCD3 bispecific antibody that redirects patients' T cells to myeloma cells which express GPRC5D. In the phase 1 MonumenTAL-1, heavily pretreated patients with a median of 6 prior lines of therapy attained a 70% response rate with 405 μg/kg of subcutaneous (SC) talquetamab. Importantly, subcutaneous talquetamab was found to be tolerable for the treated population, which included 28% of patients aged ≥70, with only three patients experiencing dose-limiting toxicities in the form of grade 3 rashes which responded to steroids. The anti-CD38 antibody daratumumab eliminates CD38-positive T and B regulatory cells, potentiates the activity of bispecific antibodies like talquetamab, and may improve its efficacy when used in combination. The aim of this study will be to assess the efficacy and safety of treating elderly patients with relapsed/refractory multiple myeloma with at least ≥2 prior lines of therapy with subcutaneous talquetamab. Patients who have progressive disease on talquetamab or who fail to respond after 3 cycles will have subcutaneous daratumumab added to their regimen.

Start Date01 Feb 2025

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

[+1]

NCT06550895

/ RecruitingPhase 2

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).

Start Date16 Sep 2024

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Talquetamab

Login to view more data

100 Translational Medicine associated with Talquetamab

Login to view more data

100 Patents (Medical) associated with Talquetamab

Login to view more data

52

Literatures (Medical) associated with Talquetamab

01 Mar 2025·EUROPEAN JOURNAL OF HAEMATOLOGY

Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions

Review

Author: Gentile, Massimo ; Vigna, Ernesto ; Puccio, Noemi ; Labanca, Caterina ; Martino, Enrica Antonia ; Mendicino, Francesco ; Bruzzese, Antonella ; Neri, Antonino ; Lucia, Eugenio ; Olivito, Virginia ; Morabito, Fortunato

ABSTRACT:

Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those with triple‐ and penta‐refractory disease. Talquetamab, recently approved by the FDA and EMA, is indicated for patients who have progressed after at least three or four prior lines of therapy (LOTs). Administered following a step‐up dosing phase to manage cytokine release syndrome (CRS), talquetamab demonstrated a high overall response rate (ORR) of approximately 70%, including in patients previously treated with T‐cell redirecting therapies. Its safety profile is consistent with other BsAbs, with hematologic adverse events such as anemia and neutropenia commonly reported, alongside unique on‐target off‐tumor toxicities like dysgeusia and skin‐related events. Infections were less frequent compared to other BsAbs. The optimal sequencing of talquetamab and other therapies, including CAR‐T cell treatments, remains an area of active research, as resistance to anti‐BCMA therapies presents ongoing clinical challenges. Current trials are exploring the use of talquetamab in combination therapies, as well as therapeutic strategies post‐treating progression. The real‐world data further support talquetamab's efficacy, making it a valuable addition to the RRMM treatment landscape.

01 Feb 2025·Clinical Lymphoma Myeloma & Leukemia

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Article

Author: Londhe, Anil ; Costa, Luciano J ; Ammann, Eric ; Peterson, Steve ; Qi, Keqin ; Parekh, Trilok ; Gray, Kathleen ; Ye, Jing Christine ; Kane, Colleen ; Biran, Noa ; Costa, Luciano J. ; Lin, Xiwu ; Nair, Sandhya ; Renaud, Thomas

BACKGROUND:

Talquetamab is approved for treatment of triple-class exposed (TCE) patients with relapsed/refractory multiple myeloma (RRMM). We evaluated the comparative effectiveness of talquetamab in the MonumenTAL-1 study versus real-world physician's choice (RW) treatment.

MATERIALS AND METHODS:

An external control arm for MonumenTAL-1 was created from patients in the Flatiron Health database who satisfied MonumenTAL-1 eligibility criteria (n = 629 with 1169 eligible lines of therapy). Patient-level data from MonumenTAL-1 were included for patients who received subcutaneous talquetamab 0.4 mg/kg QW (n = 143) and 0.8 mg/kg Q2W (n = 145). After adjusting for baseline covariate imbalances, comparative effectiveness was assessed for progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS).

RESULTS:

Baseline covariates were comparable across cohorts after adjustment. Talquetamab 0.4 mg/kg QW and 0.8 mg/kg Q2W cohorts, respectively, showed significant improvement in PFS (HR, 0.55 [95% CI, 0.44-0.69; P < .0001; median, 7.5 vs. 4.0 months] and 0.40 [95% CI, 0.31-0.53; P < .0001; median, 14.2 vs. 4.0 months]), TTNT (HR, 0.59 [95% CI, 0.47-0.74; P < .0001; median, 9.1 vs. 5.1 months] and 0.45 [95% CI, 0.35-0.59; P < .0001; median, 13.3 vs. 5.1 months]), and OS (HR, 0.56 [95% CI, 0.40-0.78; P = .0007; median, NR vs. 16.5 months] and 0.48 [95% CI, 0.33-0.70; P = 0.0002; median NR vs. 15.9 months]) versus RW treatment.

CONCLUSION:

Both talquetamab schedules demonstrated superior effectiveness over RW treatment for all outcomes assessed. These data suggest talquetamab as an effective immunotherapy option in patients with TCE RRMM.

09 Jan 2025·NEW ENGLAND JOURNAL OF MEDICINE

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Article

Author: Krevvata, Maria ; Min, Chang-Ki ; Morillo, Daniel ; Ocio, Enrique M ; Vanak, Jill ; Avivi, Irit ; Quijano Cardé, Natalia A ; Cohen, Yael C ; Di Scala, Lilla ; Mateos, María-Victoria ; Banerjee, Arnob ; Yoon, Sung-Soo ; Rodríguez-Otero, Paula ; Kim, Kihyun ; Magen, Hila ; Oriol, Albert ; Hilder, Brandi ; Chu, Michael P ; Kumar, Ashwini ; Scott, Emma ; Sebag, Michael ; Gatt, Moshe ; Peterson, Michelle R

BACKGROUND:

Talquetamab (anti-G protein-coupled receptor family C group 5 member D) and teclistamab (anti-B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class-exposed relapsed or refractory multiple myeloma.

METHODS:

We conducted a phase 1b-2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. In phase 1, we investigated five dose levels in a dose-escalation study. Talquetamab at a dose of 0.8 mg per kilogram of body weight plus teclistamab at a dose of 3.0 mg per kilogram every other week was selected as the recommended phase 2 regimen. The primary objective was to evaluate adverse events and dose-limiting toxic effects.

RESULTS:

A total of 94 patients received treatment, with the recommended phase 2 regimen used in 44. The median follow-up was 20.3 months. Three patients had dose-limiting toxic effects (including grade 4 thrombocytopenia in 1 patient with the recommended phase 2 regimen). Across all dose levels, the most common adverse events were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Grade 3 or 4 adverse events, most commonly hematologic events, occurred in 96% of the patients. Grade 3 or 4 infections occurred in 64% of the patients. With the recommended phase 2 regimen, a response occurred in 80% of the patients (including in 61% of those with extramedullary disease); across all dose levels, a response occurred in 78%. The likelihood of patients continuing in response at 18 months was 86% with the recommended phase 2 regimen (82% among those with extramedullary disease) and 77% across all dose levels.

CONCLUSIONS:

The incidence of grade 3 or 4 infections with talquetamab plus teclistamab was higher than has been observed with either therapy alone. A response was observed in a high percentage of patients across all dose levels, with durable responses with the recommended phase 2 regimen. (Funded by Janssen Research and Development; RedirecTT-1 ClinicalTrials.gov number, NCT04586426.).

96

News (Medical) associated with Talquetamab

22 Jan 2025

·www.biopharmadive.com

J&J oncology sales grow, but shares slide on outlook

Dive Brief:Johnson & Johnson on Wednesday reported modestly higher-than-expected earnings for the fourth quarter, while cautioning that unfavorable currency exchange rates would temper sales growth this year.Adjusted earnings per share reached $2.04 in the fourth quarter, higher than the Wall Street consensus of $2.01 and Leerink Partners estimate of $1.96, Leerink analyst David Risinger wrote in a note to clients. The companys sales rose 5.3% to $22.5 billion during the quarter, in line with estimatesFull-year 2024 revenue increased to $88.8 billion from $85.2 billion in 2023. For this year, J&J expects revenue to climb to between $89.2 billion and $90 billion, with a mid-point of $89.6 billion, less than the consensus estimate of $91.1 billion. Shares of the company dropped about 3% in early trading Wednesday, even as the overall market rose.Dive Insight:CEO Joaquin Duato is looking to newer medicines to drive J&Js sales growth as the company fights through generic competition for its second-best selling drug, Stelara. Worldwide sales of Stelara dropped 15% to $2.3 billion in the fourth quarter, with most of the decline coming from overseas, where copycat competition already has a toehold. In the U.S., Amgen recently launched the first biosimilar of Stelara and more are on the way.Even so, J&J is poised for sustained growth through this decade, Duato said. I cannot think of any other company that would be able to deliver growth through the first year of losing exclusivity of a multibillion-dollar product, Duato told analysts on a conference call.That growth will depend in large part on the continued success of the companys cancer medicines, led by Darzalex. Sales of the drug jumped 21% to $3.1 billion in the fourth quarter. At the same time, J&Js Carvykti, a CAR-T treatment for multiple myeloma, came close to breaking $1 billion in sales for the year. J&J will also be looking for growth from newer medicines including Tecvayli and Talvey.Outside of oncology, J&Js depression treatment Spravato brought in sales of $1.1 billion for the year, a 56% increase from the previous year. And the drug will benefit in 2025 from an expanded Food and Drug Administration approval in people with treatment-resistant depression.J&J also plans to expand its psychiatric offerings with the $14.6 billion acquisition of Intra-Cellular Therapies announced last week. Intra-Cellular sells a drug called Caplyta for schizophrenia and bipolar disorder and is looking to expand its use for patients with major depressive disorder. '

AcquisitionCell Therapy

09 Jan 2025

·www.drugs.com

Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma

THURSDAY, Jan. 9, 2025 -- For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according to a study published in the Jan. 9 issue of the New England Journal of Medicine . Yael C. Cohen, M.D., from the Tel Aviv Sourasky Medical Center in Israel, and colleagues conducted a phase 1b-2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. Five dose levels were investigated in a dose-escalation study in phase 1. The recommended phase 2 regimen was talquetamab at a dose of 0.8 mg/kg body weight plus teclistamab at a dose of 3.0 mg/kg every other week. The primary objective of the study was to evaluate adverse events and dose-limiting toxic effects. Ninety-four patients received treatment; 44 used the recommended phase 2 regimen. Patients were followed for a median of 20.3 months. The researchers found that three patients had dose-limiting toxic effects (including one with grade 4 thrombocytopenia, who received the recommended phase 2 regimen). The most common adverse events across all dose levels were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Ninety-six percent of patients had grade 3 or 4 adverse events, most often hematologic events. Sixty-four percent of patients had grade 3 or 4 infections. A response occurred in 80 percent of the patients with the recommended phase 2 regimen and in 78 percent across all dose levels. The likelihood of patients continuing in response at 18 months was 86 and 77 percent with the recommended phase 2 regimen and across all dose levels, respectively. "On the basis of these results, this dual-targeting, off-the-shelf combination therapy warrants further investigation in patients with relapsed or refractory multiple myeloma," the authors write. The study was funded by Janssen, which manufactures talquetamab and teclistamab.

Clinical ResultPhase 2Phase 1Phase 3

31 Dec 2024

·www.echemi.com

7 New Drugs Expected to Be Approved in 2025

In 2024, China approved several new drugs, and more blockbuster drugs are expected to be launched in 2025, covering oncology, autoimmune diseases, rare diseases, and other therapeutic areas. Drug Name Mechanism of Action Indications Development Institutions Evantuzumab c-Met/EGFR bispecific antibody Non-small cell lung cancer Johnson & Johnson; Genmab Taqetuzumab CD3/GPRC5D bispecific antibody Multiple myeloma Johnson & Johnson; Genmab Zenidatuzumab Anti-HER2 bispecific antibody Biliary tract cancer Zymeworks; Jazz Pharmaceuticals; BeiGene Inalises PI3Kα inhibitor HR-positive breast cancer Roche; Chugai Pharmaceutical Asunitinib STAMP allosteric inhibitor Speculated use for chronic myeloid leukemia treatment Novartis Tazemetostat EZH2 inhibitor Follicular lymphoma Epizyme; Huadong Medicine; Eisai Relatuzumab-alpha PDL1/TGF-β bispecific antibody Stomach cancer; gastroesophageal junction cancer Hengrui Medicine; Dong-A Pharma Vabysmo EGFR antibody-drug conjugate Nasopharyngeal cancer Lepu Biopharma Tenapanor NHE3 inhibitor Chronic kidney disease hyperphosphatemia Ardelyx; Kyowa Kirin; Fosun Pharma; AstraZeneca Mersutide OXM analog; GLP-1R/GCGR agonist Obesity Eli Lilly; Innovent Biologics Vusirumab IL-1β monoclonal antibody Gouty arthritis Junshi Biosciences Romosozumab SOST monoclonal antibody Osteoporosis Astellas; Amgen; UCB Teplizumab CD3 monoclonal antibody Type 1 diabetes Ligand Pharmaceuticals; Johnson & Johnson; Sanofi Solrepinib Syk inhibitor Immune thrombocytopenic purpura Huadong Medicine BBM-H901 Factor IX gene therapy Hemophilia B Gene Therapy Fitusiran RNAi therapy Hemophilia A; Hemophilia B Sanofi; Alnylam Andexanet alfa Recombinant factor Xa Factor Xa inhibitor antidote Portola Pharmaceuticals Lisocabtagene maraleucel IL-23p19 monoclonal antibody Crohn's disease Boehringer Ingelheim; AbbVie Lemborexant & Daridorexant OX1R antagonist; OX2R antagonist Insomnia Eisai & Idorsia; Sihuan Pharmaceutical; Nxera Pharma Highlights of new drug approvals in 2024 include: 1. Oncology: The world’s first antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) for ovarian cancer: Mirvetuximab soravtansine. PD-1/VEGF bispecific antibody envafolimab and Nectin-4 ADC enfortumab vedotin. 2. Autoimmune diseases: IL-17A/F monoclonal antibody bimekizumab for ankylosing spondylitis. 3. Rare diseases: Novartis’ complement factor B inhibitor for paroxysmal nocturnal hemoglobinuria (PNH). Blockbuster drugs expected to be approved in 2025 include: Oncology: Amivantamab (Q1) The world’s first c-Met/EGFR bispecific antibody. Highlight: Phase III study showed significant extension of median progression-free survival (mPFS). Talquetamab (Q2) A CD3/GPRC5D bispecific antibody and the world’s first drug targeting GPRC5D. Clinical results: Objective response rate (ORR) in Chinese patients was 69.0%-73.6%. Zanidatamab (Q2) A HER2-targeting bispecific antibody based on Azymetric™ technology. Indication: HER2-positive biliary tract cancer (BTC) with an ORR of up to 52%. Inavolisib (Q3) Roche’s highly selective PI3Kα inhibitor for PIK3CA-mutated breast cancer. Asciminib (Q3) Novartis’ Bcr-Abl allosteric inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia (CML). SHR-1701 (Q4) A PD-L1/TGF-βRII bifunctional fusion protein for first-line treatment of gastric cancer. Phase III study demonstrated significant extension in median overall survival. MRG003 (Q4) China’s first EGFR-targeting ADC with remarkable efficacy in nasopharyngeal carcinoma. Endocrinology and Metabolism: Tenapanor (Q1) The world’s only approved NHE3 inhibitor for controlling hyperphosphatemia in chronic kidney disease patients. Trend Analysis: Continued Innovation in Oncology: The emergence of multiple bispecific antibodies and ADC drugs is making targets and treatment options more precise and diverse. Breakthroughs in Autoimmune and Rare Diseases: New biologics are gradually addressing drug resistance and limited treatment options in previous therapies. Emergence of Domestic Innovative Drugs: Examples include SHR-1701 and MRG003, highlighting the growing research and development capabilities of Chinese pharmaceutical companies. The sequential launch of these drugs will provide new therapeutic options for Chinese patients and enhance China’s position in the global pharmaceutical market.

Drug ApprovalPhase 3Clinical ResultADCImmunotherapy

100 Deals associated with Talquetamab

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	US	Janssen Biotech, Inc.	09 Aug 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	US	Janssen Research & Development LLC	20 Oct 2022
Refractory Multiple Myeloma	Phase 3	PL	Janssen Research & Development LLC	20 Oct 2022
Peripheral Stem Cell Transplantation	Phase 2	US	Janssen Scientific Affairs LLC	01 Nov 2025
Smoldering Multiple Myeloma	Phase 2	US	Janssen Scientific Affairs LLC	04 Dec 2023
Relapse multiple myeloma	Phase 2	US	Janssen Research & Development LLC	01 Feb 2021
Relapse multiple myeloma	Phase 2	CN	Janssen Research & Development LLC	01 Feb 2021
Relapse multiple myeloma	Phase 2	JP	Janssen Research & Development LLC	01 Feb 2021
Relapse multiple myeloma	Phase 2	BE	Janssen Research & Development LLC	01 Feb 2021
Relapse multiple myeloma	Phase 2	FR	Janssen Research & Development LLC	01 Feb 2021
Relapse multiple myeloma	Phase 2	DE	Janssen Research & Development LLC	01 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04586426 (RedirecTT-1, Pubmed) Manual	Phase 1/2	Multiple Myeloma \| Refractory Multiple Myeloma	94	Talquetamab + Teclistamab	hcayvjjbwq(tjwxhxzruj) = wcmquxcqpl txoprwwryt (upvgfhbaju ) View more	Positive	09 Jan 2025
				Talquetamab 0.8 mg/kgTalquetamab 0.8 mg/kg + Teclistamab 3.0 mg/kgTeclistamab 3.0 mg/kg (RP2R)	dutgltygbu(pkkapqejcd) = gzhcszboej oszfrzmaww (cicrqmysae ) View more
NCT04586426 (RedirecTT-1, Pubmed \| N Engl J Med)	Phase 1/2	Refractory Multiple Myeloma	94	Talquetamab 0.8 mg/kg + Teclistamab 3.0 mg/kg	opwkojaxxm(iqqrjnphkt) = yhijhyhnpy ypnqvaotpv (xezshtxmsh ) View more	Positive	09 Jan 2025
ASH2024	Not Applicable	Refractory Multiple Myeloma	-	Talquetamab 0.4 mg/kg weekly	kkccxvompw(xwhodctuge) = wkhsbintjs icuzqxbjwb (xpijfvtcef ) View more	-	08 Dec 2024
				Talquetamab 0.8 mg/kg every other week	kkccxvompw(xwhodctuge) = cgitkwopjm icuzqxbjwb (xpijfvtcef ) View more
ASH2024	Not Applicable	Multiple Myeloma	-	Talquetamab 0.6 mg/kg Q2W	bcsoywrtkw(zpodnjukaw) = Cytokine release syndrome (CRS) were graded by American Society of Transplantation and Cellular Therapy criteria; all other adverse events (AEs) were graded by Common Terminology Criteria for Adverse Events v5.0. nzgbowxbri (lkrczqudib ) View more	-	07 Dec 2024
				Talquetamab 0.8 mg/kg Q4W
NCT03399799 \| NCT04634552 (MonumenTAL-1, SOHO2024)	Phase 1/2	Multiple Myeloma GPRC5D \| CD3	375	Talquetamab 0.4 mg/kg QW	yyrutmmhmu(zfotjbcbii) = Early onset of GPRC5Drelated AEs was associated with a higher likelihood of response mgpcyokjvu (jtneyoegtr ) View more	Positive	04 Sep 2024
				Talquetamab 0.8 mg/kg Q2W
SOHO2024	Not Applicable	Multiple Myeloma	-	Talquetamab 0.4 mg/kg QW	uatqdtpdfu(mjetlhizzs) = 74.3% (most grade 1/2, 1 grade 3) etxnvfiwmg (vcjilfngas ) View more	-	04 Sep 2024
				Talquetamab 0.8 mg/kg Q2W
NCT03399799 \| NCT04634552 (MonumenTAL-1, ASCO2024) Manual	Not Applicable	Multiple Myeloma	21	Talquetamab	zijpkwttcj(mwlccjrxqx) = aizumnsxgy canmddvvxg (fgpnuawczc ) View more	Positive	24 May 2024
ASCO2024	Not Applicable	Multiple Myeloma	-	Talquetamab	gjanftyuch(mankvxgljm) = Cytokine release syndrome occurred in 12 patients (70.6%), with 5 patients (29.4%) in grade 2 or higher CRS yokgdmaolk (zrfyavwask ) View more	-	24 May 2024
NCT05050097 (MonumenTAL-2, EHA 12024 \| EHA 22024) Manual	Phase 1	Multiple Myeloma Third line	35	Talquetamab 0.4 mg/kg weekly	dledpfhqnz(rmpcbfhhbv) = Grade 3/4 AEs occurred in 91.4% of pts kfwbidtiej (vfioqnfroq )	Positive	14 May 2024
				Talquetamab 0.8 mg/kg every other week
NCT03399799 \| NCT04634552 (MonumenTAL-1, EHA 12024 \| EHA 22024) Manual	Phase 1/2	Multiple Myeloma Last line	375	Talquetamab QW cohort	cktkjqoctm(onhifngcwn) = cauqrionzu gtdlknufyl (zduztskqgn ) View more	Positive	14 May 2024
				Talquetamab Q2W cohort	cktkjqoctm(onhifngcwn) = xovklqvpgx gtdlknufyl (zduztskqgn ) View more